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Abstract
Purpose The two main etiological factors for vulvar squamous cell carcinoma (vSCC) are the vulvar dermatosis lichen 
sclerosus (LS) and high-risk human papillomavirus (hrHPV). Serpin A1 (α1-antitrypsin) is a serine protease inhibitor, which 
plays a role in the tumorigenesis of various cancer types. The aim of the study was to evaluate the expressions of Serpin 
A1 in LS, premalignant vulvar lesions, and vSCC using immunohistochemistry (IHC) and serum analysis, and to compare 
Serpin A1 stainings to the tumor markers p53 and p16.
Methods In total, 120 samples from 74 patients were studied with IHC for Serpin A1, p53 and p16: 18 normal vulvar skin, 
53 LS, 9 premalignant vulvar lesions (dVIN/HSIL) and 40 vSCC samples. Serum concentrations of Serpin A1 were analyzed 
from 30 LS, 44 vSCC and 10 control patients. Expressions were compared to clinical data.
Results Tumor cell-specific Serpin A1 overexpression was detected in 88% of vSCC samples, independent of the etiology. 
The intensity of Serpin A1 expression was significantly higher in vSCC than in healthy vulvar skin, LS, or premalignant 
vulvar lesions. Serpin A1 showed an association with p53 positivity. No difference in overall survival was found between 
Serpin A1-, p53-, or p16-positive vSCC patients. Serum concentrations of Serpin A1 were equal in the LS, vSCC, and 
control groups.
Conclusion Tumor cell-specific Serpin A1 overexpression is a potential biomarker in vSCC.
Keywords Lichen sclerosus · Vulvar squamous cell carcinoma · Serpin A1 · p53 · p16
Introduction
Vulvar squamous cell carcinoma (vSCC) accounts for 
approximately 5% of the tumors of the female genital tract 
and has two main etiologies: high-risk human papilloma-
virus (hrHPV) and the chronic vulvar dermatosis lichen 
sclerosus (LS) [1]. LS-dependent vSCC typically affects 
elderly women (on average, 60–80 years of age), while HPV-
dependent vSCC occurs at a younger age and is associated 
with the number of sexual partners, smoking, and immuno-
logical deficiencies [2]. These two pathways differ from each 
other by their precursor lesions, which are differentiated vul-
var intraepithelial neoplasia (dVIN) for LS-dependent and 
high-grade squamous intraepithelial lesions (HSIL, previ-
ous WHO nomenclature usual VIN2-3) for HPV-depend-
ent vSCC, but also by their genetic alterations and protein 
markers [3]. TP53 mutations, which are detectable by means 
of immunohistochemical (IHC) methods, showing either a 
p53-positive or p53-null staining pattern, are considered as 
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a hallmark of the carcinoma process related to LS [2, 3]. On 
the other hand, intensive p16 staining is a surrogate marker 
of hrHPV infection [4]. The difference in survival between 
these two groups has remained controversial [1, 2]. How-
ever, the pathways overlap with respect to their clinical and 
histological features, as well as their IHC findings. Overall, 
the understanding of the pathogenetic mechanisms of malig-
nant progression especially in LS-dependent SCC is limited, 
and biomarkers are warranted for clinical use [5].
Serpin peptidase inhibitor clade A member 1 (Serpin A1), 
also called α1-antitrypsin, is a serine protease inhibitor [6]. 
Serpin A1 is an acute-phase protein that effectively inhibits 
the activity of neutrophil elastase, and also that of, for exam-
ple, trypsin, chymotrypsin, plasmin, and thrombin [7]. Ser-
pin A1 plays a role in blood coagulation, angiogenesis, and 
the remodeling of the extracellular matrix [8]. Various tumor 
cells also produce Serpin A1 [6]. Serpin A1 has been shown 
to exert an anti-apoptotic and tumor-promoting effect and 
is considered a marker for poor prognosis in gastric, lung, 
colorectal, ovarian, and cervical cancer [6, 9–12]. Overex-
pression of the Serpin A1 gene is associated with cutaneous 
SCC and the progression of esophageal squamous dysplasia, 
and plasma levels of Serpin A1 are elevated in esophageal 
SCC as well as gastric, prostate, lung, and colorectal cancer 
[13–19].
The expression of Serpin A1 is associated with various 
cancer types, including SCC, but has not previously been 
studied in vSCC. The aim of our study was to evaluate the 
role of Serpin A1 in the malignant progression of vSCC 
using IHC and serum analysis, as well as to compare the Ser-
pin A1 expressions to tumor markers p53 and p16 in vSCC.
Materials and methods
The Ethics Committee of Tampere University Hospital 
approved the study protocol (R11026) and the Finnish 
National Supervisory Authority for Welfare and Health gave 
its official permission for the use of diagnostic histological 
LS and vulvar SCC samples (D9050/06.01.03/2013). Serum 
samples and healthy vulvar skin biopsies were obtained from 
volunteer patients being treated at the Department of Gyne-
cology and Obstetrics of Tampere University Hospital. All 
volunteers gave their informed consent for the study. The 
patient records were accessed with the permission of the 
medical director of Tampere University Hospital to verify 
the course and staging of the disease.
Patients and samples
The study included a total of 120 biopsy and vulvec-
tomy samples from LS and vSCC patients treated at the 
Department of Gynecology or the Department of Derma-
tology at Tampere University Hospital in 2006–2008 and 
2010–2013.
Healthy vulvar skin tissue samples were obtained from 18 
volunteer vSCC patients and the biopsies were taken from 
healthy-looking skin in the vulvar area. The study included 
30 patients with vulvar LS without malignant progression 
(aged 42–86 years, median 71 years) and 40 patients with 
vSCC (aged 39–90 years, median 72 years). LS was his-
tologically verified by dermatopathologist R.H-O in 24 
(60%) of vSCC patients. No other vulvar dermatoses were 
detected in the vSCC patients. The majority of the LS sam-
ples without malignant progression were diagnostic (26/30) 
and were taken before potent corticosteroid treatment. Only 
three LS patients with malignant progression were on potent 
corticosteroid treatment prior to the biopsies. Six HSIL and 
three dVIN samples surrounding the carcinoma area were 
also available. The clinical data, including FIGO staging and 
lymph node status, the histological grade of the tumor, and 
recurrence time, were available for all vSCC patients, and 
data on the tumor size and invasion depth were available for 
34 of the vSCC patients.
Serum samples were collected from 84 volunteers: 29 
patients with vSCC before surgical treatment, 15 surgically 
treated vSCC patients during follow-up (on average 2.6 years 
after surgery), 30 LS patients and 10 age-matched uterine 
prolapse patients serving as controls. Patients with a history 
of any other tumors and those with an acute infection or 
other inflammatory diseases were excluded.
Immunohistochemical studies
All tissue samples were formalin-fixed paraffin-embedded. 
The Serpin A1 stainings were performed with the poly-
clonal rabbit anti-human Serpin A1 antibody (ATT, code 
no A0012, DakoCytomation) using an automated immu-
nostaining device (Ventana Medical Systems SA, Illkirch, 
France) and the Ventana UltraView Universal DAB detec-
tion kit and the Ventana amplification kit (Ventana Medical 
Systems SA). The dilution used was 1:7000. Liver tissue was 
used as a positive control.
p53 and p16 stainings were performed with prediluted 
mouse monoclonal antibodies anti-p53 (Bp53-11, cat.nro. 
760-2542, Ventana Medical Systems, Inc.) and CINtec p16 
histology (E6H4, cat.nro. 725-4713, Ventana Medical Sys-
tems, Inc.) using a Ventana BenchMark immunostainer and 
Ventanan Ultraview DAB Detection Kit (Ventana, Tucson, 
Arizona) according to the manufacturer’s instructions. Ultra-
block antibody diluent (cat.nro. 251-018, Ventana Medical 
Systems, Inc.) was used for p16 staining. High-grade serose 
adenocarcinoma and cervical carcinoma in situ were used as 
positive controls for p53 and p16, respectively.
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All samples were analyzed independently by a dermato-
pathologist (R.H-O) and author 1. Cytoplasmic staining of 
Serpin A1 was considered specific and the staining inten-
sity was scored as follows: negative (0), weak (+), moderate 
(++), and strong/positive control (+++). The staining inten-
sity was evaluated from the most invasive area of the tumor.
In our study p53 staining was scored < 1% or null, 1–10% 
or normal, 10–50% and > 50% of the tumor cell nuclei posi-
tive, but only more than 50% of the tumor nuclei stained 
was considered positive for statistical analysis, in accordance 
with clinical practice. In LS, both continuous and discon-
tinuous basal epidermal keratinocyte staining was consid-
ered positive. Less than 10% nuclei positivity in LS was 
considered negative in accordance with normal vulvar skin 
where single epidermal keratinocytes and melanocytes stain.
Staining for p16 was interpreted as positive when over 
75% of the cells showed intensive cytoplasmic and nuclear 
staining, i.e., so-called “block positivity.”
Serum sample preparation and analysis of Serpin A1 
serum levels
The serum samples were collected into Venosafe serum 
tubes, centrifuged 2000g for 10 min and stored in cryotubes 
at − 70 °C until use. An immunonephelometric assay (BM 
ProSpec automatic analyzer, Siemens Healthcare Diagnos-
tics Inc., Siemens Aktiengesellschaft, Munich, Germany) 
was used for the analysis of Serpin A1 serum concentrations.
Statistics
Pearson’s Chi square test was used to compare the Serpin A1 
staining intensity between different patient groups. Fisher’s 
exact test was used to determine the association between 
Serpin A1 staining and categorical variables (histological 
grade, FIGO staging, and immunopositivity of p53 and p16). 
Kaplan–Meier analysis was used to compare the overall 
survival in LS-, p53- and p16-positive and negative vSCC 
patients, and in the comparison of Serpin A1 intensity and 
survival.
Results
The epidermal layer of healthy vulvar skin was negative for 
Serpin A1 staining (Fig. 1a). Of all the 53 LS samples 40% 
were negative, whereas 26% showed weak (+) (Fig. 1b) 
and 30% moderate (++) cytoplasmic Serpin A1 staining. 
Only 4% of the LS samples showed strong (+++) staining. 
LS without malignant progression showed more intensive 
Serpin A1 staining than LS samples from vSCC patients 
(p = 0.024*). Four LS patients without malignant progres-
sion had used potent corticosteroid treatment prior the 
biopsy, and the biopsy samples of three of them showed 
negative staining for Serpin A1. There was a statistically 
significant correlation between negative staining for Serpin 
A1 and treatment with potent corticosteroids in this patient 
Fig. 1  Expressions of Serpin A1 in vulvar skin, lichen sclerosus (LS), 
differentiated vulvar intraepithelial lesions/high-grade squamous 
intraepithelial lesions (dVIN/HSIL), and vulvar squamous cell carci-
noma (vSCC). a The epidermal layer of healthy vulvar skin is nega-
tive for Serpin A1. b Weak (+) cytoplasmic staining of the epider-
mis in LS, c moderate-intensity (++) staining of dVIN, and d strong 
(+++) tumor cell-specific staining in vSCC. e Semiquantitative anal-
ysis of Serpin A1 staining in healthy vulvar skin (n = 18), LS without 
vSCC (n = 30), LS with vSCC (n = 23), dVIN/HSIL (n = 9), p16-neg-
ative vSCC (n = 30) and p16-positive vSCC (n = 10). ***p < 0.001, 
**p < 0.01, *p < 0.05 (χ2 test). Original magnifications × 200
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group (p = 0.01**). In LS samples from vSCC patients the 
correlation between Serpin A1 staining and corticosteroid 
treatment was not detected. The staining intensity in prema-
lignant vulvar lesions was equal in HSIL and dVIN samples 
and showed weak or moderate staining (Fig. 1c) in 67% of 
the samples, being negative for Serpin A1 in 33% of the sam-
ples. The majority (75%) of the 40 vSCC samples showed 
tumor cell-specific strong (Fig. 1d) or moderate cytoplasmic 
staining for Serpin A1, and weak tumor cell-specific staining 
was detected in 13% of the vSCC samples. The expression of 
Serpin A1 was significantly higher in vSCC than in healthy 
vulvar skin, LS, or HSIL/dVIN samples (Fig. 1a–e). Serpin 
A1 staining intensity did not correlate with the histological 
grade of the tumor, the FIGO staging, the recurrence, the 
lymph node status, the depth of tumor invasion (< 4 mm 
vs. > 4 mm), or the tumor size (< 40 mm vs. > 40 mm) of 
the vSCC patients.
Positive p16 staining, indicating hrHPV positivity, was 
detected in 10 (25%) of the vSCC samples and 50% of HSIL 
samples (Table 1, Fig. 2a, b). LS and p16 positivity coex-
isted in three out of all 40 vSCC cases (8%). All LS samples 
were interpreted as negative for p16, but mild/mosaic basal 
epidermal p16 staining was already apparent in LS samples 
from next to a p16-positive tumor (Fig. 2c).
Positive p53 staining was detected more frequently in 
p16-negative (57%) than p16-positive vSCC (30%) samples, 
and p53-null staining was detected in 23% of the vSCC sam-
ples (Table 1, Fig. 3a, b, respectively). For tissue samples 
from two vSCC patients p53 data were not available. The LS 
samples from vSCC patients showed continuous or discon-
tinuous “band-like” p53 positivity in basal epidermal cells in 
35% of the samples, while LS without malignant progression 
was p53-positive in 93% of the cases, and the difference was 
Table 1  p53 and LS status in both p16-positive and p16-negative 
vulvar squamous cell carcinoma (vSCC), high-grade intraepithe-
lial lesion (HSIL) and differentiated vulvar intraepithelial neoplasia 
(dVIN) tissue samples
p53 data not available from two p16-negative vSCC patients
LS lichen sclerosus
Samples vSCC, p16+
n = 10
vSCC, p16−
n = 30
HSIL
n = 6
dVIN
n = 3
p53-positive (%) 3 (30%) 17 (57%) 3 (50%) 1 (33%)
p53-null (%) 4 (40%) 5 (17%) 2 (33%) 1 (33%)
LS-positive (%) 3 (30%) 27 (90%) 2 (33%) 3 (100%)
Fig. 2  Expression of tumor marker p16 in vSCC and LS. a Intensive 
nuclear and cytoplasmic p16 positivity in vSCC; b p16 positivity in 
transition to HSIL; and c mosaic/mild epidermal p16 staining in LS 
adjacent to p16 positive vSCC, interpreted as p16 negative. Original 
magnifications × 200
Fig. 3  Expression of tumor marker p53 in vSCC and LS. a p53-posi-
tive staining (over 50% of tumor nuclei stained) in vSCC; b p53-null 
staining (< 1% of tumor nuclei stained) in vSCC; and c p53-positive 
“band-like” staining in the nuclei of basal epidermal keratinocytes in 
LS. Original magnifications × 200
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statistically significant (p < 0.001***) (Fig. 3c). Six (15%) 
of the 40 vSCC samples were negative for both p53 and 
p16, and of four (67%) out of the six samples showed strong 
or moderate Serpin A1 staining. There was a statistically 
significant correlation between p53 positivity and Serpin 
A1 positivity (p = 0.017*) in vSCC, but Serpin A1 and p16 
positivity showed no association. No statistically signifi-
cant difference in overall survival was observed in vSCC 
patients with and without LS, but the mean survival was 
better in the LS-negative vSCC patient group (6.3 years vs. 
5.6 years, respectively). The overall survival of our vSCC 
patients showed no correlation with Serpin A1 intensity, nor 
with p53 or p16 positivity. The average follow-up time was 
8.1 years (range 3.2–11.0 years) from diagnosis to the end of 
the study period with exitus in 25/40 (63%) of the patients.
No statistically significant differences were detected in 
Serpin A1 serum concentrations between the active vSCC, 
treated vSCC, LS or control groups. The mean respective 
values and ranges were 1.483 g/l (0.893–2.05 g/l), 1.463 g/l 
(1.17–1.77 g/l), 1.438 g/l (0.95–1.78 g/l) and 1.472 g/l 
(1.15–2.01 g/l). The normal range for Serpin A1 serum con-
centrations is 0.96–1.78 g/l.
Discussion
To our knowledge, this was the first study showing tumor 
cell-specific Serpin A1 overexpression in vSCC. The expres-
sion of Serpin A1 was significantly increased in vSCC com-
pared to healthy vulvar skin, LS, and premalignant vulvar 
lesions. The overexpression of Serpin A1 was independent 
of the etiology of vSCC and, therefore, connects the two 
inflammatory etiologies of vSCC. Positivity of p53 was 
associated with Serpin A1 overexpression in vSCC, but no 
correlation was detected between Serpin A1 and the histo-
logical grade of the tumor, the FIGO staging or the survival 
of our patients.
Serpin A1 overexpression is a marker of poor prognosis 
in various cancer types [6, 9–13, 15, 20]. Primary tumor 
cells and metastases produce Serpin A1, and elevated 
plasma concentrations have been detected in SCC of the 
esophagus and oral cavity, among others [15–19, 21]. Our 
study revealed no difference in Serpin A1 serum concen-
trations between controls, LS, and vSCC patients. Due to 
the physiological function of Serpin A1 as an acute-phase 
protein, its serum concentration may thus not be sensitive 
enough for the evaluation of malignant progression in vSCC.
Several tumorigenic mechanisms of Serpin A1 have been 
identified. Serpin A1 mediates anti-apoptotic effects through 
the TNFα-signaling pathway, but also directly via block-
ing caspase-3 activity [22]. In addition, in gastric, ovarian, 
breast, colorectal, and lung cancer cells, Serpin A1 promotes 
tumor cell migration and invasion capacity [6, 10, 11, 23, 
24]. Serpin A1 has a role in angiogenesis, complement acti-
vation and the remodeling of the extracellular matrix, thus 
making it a factor of the tumor microenvironment [8]. Even 
though there is an increasing understanding of the role of 
chronic inflammation and the tumor microenvironment in 
cancer progression, previous studies on the vSCC tumor 
microenvironment are limited [25, 26]. The present study 
found a novel agent, Serpin A1, in the microenvironment 
of vSCC.
Serpin A1 plays a role in the regulation of inflammation 
and autoimmunity [7]. Serpin A1 expression is enhanced by 
the cytokines EGF, TNF-α, INF-γ, and IL-1β in cutaneous 
SCC cells and the latter three are also upregulated in lichen 
sclerosus [13, 26]. In other autoimmune diseases, such as 
SLE, rheumatoid arthritis, and diabetes mellitus type 1, the 
role of Serpin A1 is anti-inflammatory and cytoprotective, 
which may explain the more abundant Serpin A1 expres-
sion in LS without malignant progression [7]. The treatment 
with potent corticosteroid ointments also seemed to correlate 
with negative Serpin A1 staining in LS without malignant 
progression. This may suggest, as noted by Lee et al. [27], 
that effective treatment of LS with potent corticosteroid oint-
ments can minimize the risk of malignant progression.
In our study, the expression of Serpin A1 increased 
gradually from LS to premalignant vulvar lesions to vSCC. 
Serpin A1 has been shown to interact with NF-κB–TNFα-
axis, an important pathway in immunology and inflamma-
tory cancers which also associates with both HPV-infection 
and lichen sclerosus [7, 25, 28]. Therefore, Serpin A1 may 
promote tumorigenesis in both pathways to vSCC.
We found a correlation between Serpin A1 overexpres-
sion and p53 positivity in our vSCC samples. A recent study 
on lung cancer shows that mutant p53 upregulates Serpin A1 
expression and promotes tumor invasion [29]. A strong asso-
ciation between LS and the LS-dependent vSCC process and 
TP53 mutations has been reported in previous studies [1–3]. 
In line with this, we observed basal epidermal p53-positivity 
in 67% of all LS samples and as frequently as in 93% of 
LS samples without malignant progression [30, 31]. This 
supports the notion that p53 positivity in LS is linked with 
ischemic stress and repairing mechanisms against stress 
rather than with the malignant potential of LS [31]. In our 
study, 50% vSCC samples showed positive staining for p53, 
which is in line with earlier studies [1, 5]. Nonsense muta-
tions of TP53 can lead to the absence of the p53 protein (so-
called p53 null), or the p53 protein can be degraded by HPV 
oncoprotein E6 [1, 3]. As many as 9/40 (23%) of our vSCC 
samples represented this p53-null type. Our results highlight 
the essential role of p53 in the malignant process of vSCC.
Interestingly, as many as 6/40 (15%) of the vSCC samples 
were both p53- and p16-negative. The majority of these sam-
ples (67%) showed strong or moderate Serpin A1 staining. A 
previous study by Nooij et al. has found this third subgroup 
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of vSCC to harbor mutations in the NOTCH1 and HRAS 
genes [32]. Therefore, the etiopathology of these p53- and 
p16-negative tumor types may be variable and constitutes an 
interesting field for future studies.
The overall survival of our vSCC patients did not corre-
late with Serpin A1, p16 or p53 positivity, but a worse prog-
nosis seemed to associate with the presence of LS. How-
ever, the number of patients in the study and also follow-up 
time were limited for survival analysis. As an interesting 
notion of study population, there were three vSCC patients 
with coexisting LS and p16 positivity. Testing for hrHPV 
could therefore be beneficial to LS patients to keep those 
patients with two risk factors for vSCC under a more inten-
sive surveillance.
Conclusion
This study found a novel biomarker, Serpin A1, to be asso-
ciated with vSCC independent of the etiology. Serpin A1 
serum concentrations or IHC showed no prognostic value 
in LS or vSCC patients. However, better understanding of 
the vSCC microenvironment may provide new avenues for 
cancer therapy studies in the future.
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